Safety, Tolerability, PK, and Efficacy Evaluation of Repeat Ascending Doses of Olipudase Alfa in Pediatric Patients <18 Years of Age With Acid Sphingomyelinase Deficiency
Clinical trial NCT02292654 · COMPLETED
Trial details
- NCT number
- NCT02292654
- Sponsor
- Genzyme, a Sanofi Company
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-05-01
- Primary completion
- 2019-12-09
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.